Day: March 17, 2022

EssilorLuxottica: SightGlass Vision Joint Venture Begins Operation

Written by Customer Service on March 17, 2022. Posted in Mergers And Acquisitions.

SightGlass Vision Joint Venture Begins Operation EssilorLuxottica and CooperCompanies initiativeaccelerates commercialization of innovative myopia management technologies Charenton-le-Pont, France and San Ramon, California (March 17, 2022) – EssilorLuxottica and CooperCompanies are pleased to announce the finalization of their joint venture agreement for SightGlass Vision. This collaboration of two global vision care leaders accelerates the commercialization of novel spectacle lens technologies to expand the myopia management category. SightGlass Vision’s Diffusion Optics Technology™ incorporates thousands of micro-dots into the lens that softly scatter light to reduce contrast on the retina, which is intended to reduce myopia progression in children.1 “As a global leader with a 30-year track record in myopia research, we have been developing...

KULR Technology Group Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

Fourth Quarter 2021 Revenue and Full-Year 2021 Revenue Up 267% and 287% Year-Over-Year Respectively SAN DIEGO, March 17, 2022 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a leading developer of next-generation lithium-ion battery safety and thermal management technologies, today announced its financial results for the fourth quarter and full-year 2021. “This past calendar year was a pivotal period in our corporate history as we achieved numerous milestones across the business,” said KULR CEO Michael Mo. “With the goal to maintain our growth trajectory, the entire team is laser focused on executing against key objectives in 2022. More specifically, we will continue to focus on the core growth sectors: energy storage, e-mobility and safe transportation of...

IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

All patients treated with INB-200, in clinical development for the treatment of glioblastoma multiforme (GBM), have shown a well-tolerated safety profile and longer than anticipated progression free survival (PFS) to date. All patients treated with INB-100, in clinical development for the treatment of leukemia undergoing hematopoietic stem cell transplantation (HSCT), have remained in remission, two for more than 1.5 years. Closed initial public offering raising gross proceeds of $40 million to advance genetically modified gamma-delta T cell therapeutic candidates into clinical development and to expand the pipeline.NEW YORK, March 17, 2022 (GLOBE NEWSWIRE) — IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing...

JOANN Announces Fourth Quarter and Full Year Fiscal 2022 Results

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

Fiscal 2022 revenue of $2.4 billion, reflecting comparable sales growth of 8.3% compared to Fiscal 2020 Net income of $56.7 million, compared to $212.3 million in Fiscal 2021 and a loss of $(546.6) million in Fiscal 2020 Two-year growth rate of 10% for gross profit and 14% for adjusted gross profit compared to Fiscal 2020 Adjusted EBITDA of $242.5 million, reflecting a two-year growth rate of 58% compared to Fiscal 2020 New strategic partnerships and newly acquired customers provide strong foundation for continued growthHUDSON, Ohio, March 17, 2022 (GLOBE NEWSWIRE) — JOANN Inc. (NASDAQ: JOAN) (“JOANN”), the nation’s category leader in sewing and one of the fastest growing competitors in the arts and crafts category, today reported results for its fourth quarter and full year ended January 29, 2022. “We’ve now completed our...

Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

Summit Therapeutics perceives multiple opportunities to expand across the microbiome therapeutics field Cambridge, MA, March 17, 2022 (GLOBE NEWSWIRE) — Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today reports its financial results and provides an update on its operational progress for the fourth quarter and year ended December 31, 2021. Note: A glossary of terms is included at the end of this document to allow for the ease of understanding of terms or concepts used throughout this release. Operational & Corporate UpdatesSummit Therapeutics intends to implement a strategy that centers on microbiome-focused therapeutics. Modern medicine is pushing the boundaries of a new, increasingly patient friendly era: successfully treating disease while reducing associated...

Embark Technology Reports Financial Results for Fourth Quarter and Full Year 2021

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

– Embark Successfully Completed Public Listing in November – – Embark Secures 14,200 Truck Reservations Under Partner Development Program – – Embark to Enable First Autonomous Trucks for Knight-Swift in 2022 as Part of Industry-First Truck Transfer Program – SAN FRANCISCO, March 17, 2022 (GLOBE NEWSWIRE) — Embark Technology, Inc. (Nasdaq: EMBK, “Embark” or the “Company”), a leading developer of autonomous technology for the trucking industry, today announced financial results for its fourth quarter ended December 31, 2021. “The past year has been momentous for Embark as we continued executing on our mission to create a safer, more efficient, and more sustainable trucking industry,” said Alex Rodrigues, CEO of Embark. “As the industry’s longest-running autonomous truck program, we continued to achieve a number of industry-firsts...

Quest Resource Holding Corporation Reports Fourth Quarter and 2021 Financial Results

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

THE COLONY, Texas, March 17, 2022 (GLOBE NEWSWIRE) — Quest Resource Holding Corporation (NASDAQ: QRHC) (“Quest” or the “Company”), a national leader in environmental waste and recycling services, today announced financial results for the fourth quarter and year ended December 31, 2021. Fourth Quarter 2021 HighlightsRevenue was $46.4 million, a 67.7% increase compared with the fourth quarter of 2020. Gross profit was $8.7 million, a 56.2% increase compared with the fourth quarter of 2020. Gross margin was 18.8% of revenue compared with 20.2% during the fourth quarter of 2020. GAAP net loss per share attributable to common stockholders was ($0.03) per basic and diluted share, compared with net income of $0.01 per basic and diluted share during the fourth quarter of 2020. Adjusted EBITDA was $3.3 million, an 83.8% increase...

CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and Provides Corporate Update

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., March 17, 2022 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the fourth quarter and fiscal year ended December 31, 2021. Sujal Shah, President and CEO of CymaBay, stated, “2021 was a year of growth for CymaBay and included accomplishments that position CymaBay for long-term success. A non-dilutive, risk-sharing development financing agreement of up to $100 million signed with Abingworth in July, together with a $75 million public equity offering in November support the completion of our ongoing Phase 3 program for seladelpar in PBC. We now have over 120 sites...

Onconova Therapeutics Reports Full Year 2021 Financial Results and Provides Business Update

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., March 17, 2022 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the twelve months ended December 31, 2021, and provided a business update. Highlights for the fourth quarter of 2021 and recent weeks include:The Phase 1 solid tumor trials of narazaciclib in the United States and China are ongoing with no dose-limiting toxicities observed to date. The trial in the United States is currently enrolling into its fourth dose cohort, which is evaluating a 160 mg daily dose administered orally on each day of a 28-day treatment cycle. The trial in China is enrolling into its fifth dose...

Ideal Power Reports Fourth Quarter and Full Year 2021 Financial Results

Written by Customer Service on March 17, 2022. Posted in Earnings Releases And Operating Results.

AUSTIN, Texas, March 17, 2022 (GLOBE NEWSWIRE) — Ideal Power Inc. (“Ideal Power” or the “Company”) (Nasdaq: IPWR), pioneering the development and commercialization of the highly efficient and broadly patented B-TRAN™ bidirectional semiconductor power switch, reported results for its fourth quarter and full year ended December 31, 2021. “Fourth quarter 2021 capped off a year of strong progress along our roadmap to commercialize B-TRAN™ as an innovative technology addressing and enabling high-growth, immediate demand markets with the potential to displace conventional power semiconductor solutions in many applications. We advanced our B-TRAN™ test and evaluation program, adding leading commercial enterprises in each of our target market segments. We also made significant progress under the U.S. Navy/Naval Sea Systems Command (NAVSEA)...

Day: March 17, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice